United States· US:0002-1445_1c6425de-1f8c-4385-bfb9-6e01db55275f
TALTZ
A ixekizumab product containing ixekizumab, registered in United States by Eli Lilly and Company. The same ATC class is registered in 14 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Ixekizumab is registered in 14 of 19 countries.
Countries holding a registration under ATC L04AC13 (ixekizumab), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 9 of them publish a price we can compare per daily dose
Ixekizumab · ATC L04AC13
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of ixekizumab costs, country by country.
Normalised to the WHO defined daily dose (2.9 mg), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Ixekizumab · price per daily dose (2.9 mg)
USD · FX 28 Sept 2026
- CH Switzerland$44.39
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- IXEKIZUMAB
- Manufacturer
- Eli Lilly and Company
- Country
- United States (US)
- ATC code
- L04AC13
- ATC class
- Ixekizumab
- Defined daily dose
- 2.9 mg, P
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 4
- ndc110002-1445-11
- ndc110002-1445-09
- ndc110002-1445-27
- ndc110002-1445-61
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
149 interactions on record for ixekizumab.
Graded by severity as the source publishes them — 27 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Ixekizumab · interactions on record
149 records
- 27 severe
- 115 moderate
- 7 minor
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Ixekizumab in 15 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaTALTZEli Lilly and Company (Ireland) Limited, Kinsale
- IrelandTaltz 40mg Solution for injectionEli Lilly Kinsale Limited
- SwitzerlandTaltz 40 mg, solution injectable en seringue préremplieEli Lilly (Suisse) SA
- FinlandTaltzEli Lilly and Company (Ireland) Limited
- BelgiumTaltz 40 mgEli Lilly and Company (Ireland)
- IcelandTaltzEli Lilly and Company (Ireland) Limited
- NetherlandsTaltz 40 mg oplossing voor injectie in voorgevulde injectiespuitEli Lilly and Company (Ireland) Limited
- SwedenTaltz 40 mg Injektionsvätska, lösning i förfylld sprutaEli Lilly And Co (Ireland) Limited
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Taltz
- Liechtenstein · Taltz
- Norway · Taltz
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/13d32624-2296-4c76-ac55-35113a160621 GET /v1/drugs/13d32624-2296-4c76-ac55-35113a160621?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "SUBCUTANEOUS",
"source": "ndc",
"strength": "80",
"substance": "IXEKIZUMAB",
"productndc": "0002-1445",
"dosage_form": "INJECTION, SOLUTION",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA125521",
"marketing_category": "BLA"
}See everything about ixekizumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.